Upregulation of CD28H or HHLA2 is anticipated to enhance antitumor immunity, as Chen et al. showed that pancreatic cancer may promote immunological escape by lowering the expression of the HHLA2 receptor CD28H on T cells [146]. This evidence concerns the gene TMIGD2 and familial pancreatic carcinoma.